Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1986 1
1990 2
1991 1
1996 1
1998 2
1999 1
2006 1
2007 1
2008 1
2009 1
2010 1
2013 1
2014 1
2015 1
2018 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma A. Shastri A, et al. Among authors: mccoon p. J Clin Invest. 2018 Dec 3;128(12):5479-5488. doi: 10.1172/JCI120156. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30252677 Free PMC article.
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. Reilley MJ, et al. Among authors: mccoon p. J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5. J Immunother Cancer. 2018. PMID: 30446007 Free PMC article. Clinical Trial.
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Proia TA, Singh M, Woessner R, Carnevalli L, Bommakanti G, Magiera L, Srinivasan S, Grosskurth S, Collins M, Womack C, Griffin M, Ye M, Cantin S, Russell D, Xie M, Hughes A, Deng N, Mele DA, Fawell S, Barry S, Reimer C, Barrett JC, McCoon P. Proia TA, et al. Among authors: mccoon p. Clin Cancer Res. 2020 Dec 1;26(23):6335-6349. doi: 10.1158/1078-0432.CCR-20-1066. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943458
Intraepithelial anchoring fibril components.
Goldsmith LA, McCoon P, Partridge A, Lane AT. Goldsmith LA, et al. Among authors: mccoon p. Arch Dermatol. 1991 Jan;127(1):53-6. Arch Dermatol. 1991. PMID: 1986707
AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors.
Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, Curt G, Eckhardt SG. Plimack ER, et al. Among authors: mccoon p. Oncologist. 2013;18(7):819-20. doi: 10.1634/theoncologist.2013-0198. Epub 2013 Jul 11. Oncologist. 2013. PMID: 23847256 Free PMC article. Clinical Trial.
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M. Hedvat M, et al. Among authors: mccoon p. Cancer Cell. 2009 Dec 8;16(6):487-97. doi: 10.1016/j.ccr.2009.10.015. Cancer Cell. 2009. PMID: 19962667 Free PMC article.
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.
Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC. Brown JL, et al. Among authors: mccoon p. Mol Cancer Ther. 2010 Jan;9(1):145-56. doi: 10.1158/1535-7163.MCT-09-0554. Epub 2010 Jan 6. Mol Cancer Ther. 2010. PMID: 20053776 Free article.
20 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page